Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 3
Submit an article Journal homepage
1,380
Views
6
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

Wojciech JurczakDepartment of Haematology, Jagiellonian University, Kraków, Poland; Correspondence[email protected]
View further author information
,
Sundra RamanathanHaematology Department, Cancer Care Centre, The St George Hospital, Kogarah, Australia; View further author information
,
Pratyush GiriLyell McEwin Hospital (LMH), Royal Adelaide Hospital (RAH), Adelaide, Australia; View further author information
,
Alessandra RomanoDivision of Hematology, A.O.U. Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy; View further author information
,
Heidi MocikovaDepartment of Clinical Hematology, University Hospital Královské Vinohrady, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; View further author information
,
Jill ClancyinVentiv Health Clinical, Princeton, NJ, USA; View further author information
,
Mariajose LechugaPfizer S.r.l, Milan, Italy; View further author information
,
Michelle CaseyPfizer Inc, Collegeville, PA, USA; View further author information
,
Joseph BoniPfizer Inc, Collegeville, PA, USA; View further author information
,
Agnieszka GizaDepartment of Haematology, Jagiellonian University, Kraków, Poland; View further author information
&
Georg HessDepartment of Hematology/Oncology, Johannes Gutenberg University, Mainz, GermanyView further author information
 show all
Pages 670-678 | Received 21 Apr 2017, Accepted 12 Jul 2017, Published online: 03 Aug 2017

References

  • Cortelazzo S, Ponzoni M, Ferreri AJ, et al. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2012;82:78–101.
  • Non-Hodgkin Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group. Blood. 1997;89:3909–3918.
  • Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29–38.
  • Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–2078.
  • Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115–127.
  • Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–565.
  • Lai R, Medeiros LJ. Pathologic diagnosis of mantle cell lymphoma. Clin Lymphoma. 2000;1:197–206. discussion 207-198.
  • Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
  • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas. NCI Sponsored International Working Group. JCO. 1999;17:1244.
  • Ansell SM, Inwards DJ, Rowland KM, Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113:508–514.
  • Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778.
  • Hess G, Coiffier B, Crump M, et al. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. Exp Hematol Oncol. 2015;4:11.
  • Trneny M, Lamy T, Walewski J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–331.
  • European Medicines Agency. Torisel® (temsirolimus) summary of product characteristics. 2009 [cited 2017 Mar 27]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000799/human_med_001098.jsp&mid=WC0b01ac058001d124.
  • Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014;28:126–133.
  • Smith SM. Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract Res Clin Haematol. 2012;25:175–183.
  • Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–3405.
  • Renner C, Zinzani PL, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012;97:1085–1091.
  • Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12:361–368.
  • Hess G, Keller U, Scholz CW, et al. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015;29:1695–1701.
  • Inwards DJ, Fishkin PA, LaPlant BR, et al. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol. 2014;25:2020–2024.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.